Centessa Pharmaceuticals PLC ADR (CNTA)

Official site

BIOTECHNOLOGY

$40.50

+0.00 (+0.00%)

Last updated: Jun 25, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

57%(12/21)

Avg Surprise

+4.54%

Upcoming Estimates

Period ending Jun 30, 2026

EPS Consensus$-0.38

Range$-0.41 - $-0.30

5 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.39+3.5%

60d ago$-0.53+28.7%

30d ago$-0.40+6.3%

7d ago$-0.40+6.3%

Current$-0.38

Revenue Consensus

Range$0 - $0

6 analysts

Period ending Sep 30, 2026

EPS Consensus$-0.39

Range$-0.42 - $-0.31

5 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.40+3.3%

60d ago$-0.55+29.1%

30d ago$-0.42+6.4%

7d ago$-0.42+6.4%

Current$-0.39

Revenue Consensus

Range$0 - $0

6 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.47	$-0.63 - $-0.42	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-0.39	$-0.42 - $-0.31	-	-	5	2 1 30d	-
Jun 30, 2026Jun 26EST	-	$-0.38	$-0.41 - $-0.30	-	-	5	2 1 30d	-
Mar 31, 2026Mar 26 Reported May 5, 2026Reported May 5	$-0.52	$-0.38	$-0.51 - $-0.35	-36.84%	Miss	5	2 1 30d	-160.0%
Dec 31, 2025Dec 25 Reported Mar 31, 2026Reported Mar 31	$-0.48	$-0.38	$-0.41 - $-0.32	-24.90%	Miss	8	-	-41.2%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.41	$-0.39	$-0.44 - $-0.32	-5.13%	Miss	9	0 3 30d	-10.8%
Jun 30, 2025Jun 25 Reported Aug 12, 2025Reported Aug 12	$-0.38	$-0.35	$-0.37 - $-0.30	-8.57%	Miss	6	No revisions (30d)	+5.0%
Mar 31, 2025Mar 25 Reported May 14, 2025Reported May 14	$-0.20	$-0.35	$-0.39 - $-0.31	+42.86%	Beat	2	1 1 30d	+47.4%
Dec 31, 2024Dec 24 Reported Mar 24, 2025Reported Mar 24	$-0.34	$-0.38	$-0.40 - $-0.31	+10.53%	Beat	4	4 0 30d	+10.5%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.37	$-0.42	$-0.44 - $-0.36	+11.90%	Beat	6	No revisions (30d)	+7.5%
Jun 30, 2024Jun 24 Reported Aug 13, 2024Reported Aug 13	$-0.40	$-0.38	$-0.44 - $-0.33	-5.26%	Miss	5	No revisions (30d)	-53.8%
Mar 31, 2024Mar 24 Reported May 13, 2024Reported May 13	$-0.38	$-0.41	$-0.44 - $-0.40	+7.32%	Beat	3	No revisions (30d)	+28.3%
Dec 31, 2023Dec 23 Reported Mar 28, 2024Reported Mar 28	$-0.38	$-0.44	$-0.60 - $-0.37	+13.64%	Beat	4	No revisions (30d)	+15.6%
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$-0.40	$-0.46	$-0.59 - $-0.45	+13.04%	Beat	4	No revisions (30d)	+29.8%
Jun 30, 2023Jun 23 Reported Aug 14, 2023Reported Aug 14	$-0.26	$-0.43	$-0.54 - $-0.40	+39.53%	Beat	5	No revisions (30d)	+62.3%
Mar 31, 2023Mar 23 Reported May 12, 2023Reported May 12	$-0.53	$-0.41	$-0.46 - $-0.36	-29.27%	Miss	3	No revisions (30d)	+11.7%
Dec 31, 2022Dec 22 Reported Mar 30, 2023Reported Mar 30	$-0.45	$-0.48	$-0.51 - $-0.44	+6.25%	Beat	3	No revisions (30d)	+33.8%
Sep 30, 2022Sep 22 Reported Nov 10, 2022Reported Nov 10	$-0.57	$-0.56	$-0.61 - $-0.52	-1.79%	Miss	2	No revisions (30d)	-26.7%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$-0.69	$-0.57	$-0.57 - $-0.57	-21.05%	Miss	2	1 0 30d	-6.2%
Mar 31, 2022Mar 22 Reported May 16, 2022Reported May 16	$-0.60	$-0.70	$-0.71 - $-0.67	+14.29%	Beat	3	No revisions (30d)	-400.0%
Dec 31, 2021Dec 21 Reported Mar 30, 2022Reported Mar 30	$-0.68	$-0.60	$-0.66 - $-0.54	-13.33%	Miss	3	No revisions (30d)	+86.3%
Sep 30, 2021Sep 21 Reported Nov 15, 2021Reported Nov 15	$-0.45	$-0.55	$-0.73 - $-0.46	+18.18%	Beat	3	No revisions (30d)	-2880.1%
Jun 30, 2021Jun 21 Reported Aug 16, 2021Reported Aug 16	$-0.65	$-0.66	$-0.66 - $-0.66	+1.52%	Beat	1	No revisions (30d)	-3010.0%
Mar 31, 2021Mar 21 Reported Jun 1, 2021Reported Jun 1	$-0.12	N/A	-	+62.50%	Beat	1	No revisions (30d)	-324.0%
Dec 31, 2020Dec 20 Reported Mar 31, 2021Reported Mar 31	$-4.97	$0.00	-	N/A	Miss	-	-	-
Sep 30, 2020Sep 20 Reported Sep 30, 2020Reported Sep 30	$-0.02	N/A	-	N/A	Beat	-	-	-
Jun 30, 2020Jun 20 Reported Jun 30, 2020Reported Jun 30	$-0.02	N/A	-	N/A	Beat	-	-	-
Mar 31, 2020Mar 20 Reported Mar 31, 2020Reported Mar 31	$-0.03	N/A	-	N/A	Beat	-	-	-

Dividends

Dividend Metrics

Forward Yield0.00%

Forward Annual Dividend$0.00

FrequencyIrregular

Pay MonthsJun

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	N/A	Operating Margin	N/A
ROE	N/A	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	N/A	Quick Ratio	N/A
Trading Statistics
Beta	N/A	Avg Volume	N/A
52-Week High	N/A	52-Week Low	N/A

Technical Indicators Dashboard

Moving Averages

SMA 10$40.06

SMA 20$39.92

SMA 50$39.72

SMA 200$29.44

EMA 10$40.16

EMA 20$39.96

EMA 50$38.61

EMA 200$30.33

MACD

Line: 0.30Signal: 0.28Hist: 0.02

ADX

ADX: 45.5+DI: 35.9-DI: 7.2

Aroon & PSAR

Aroon Up92.0

Aroon Down56.0

PSAR$39.68

Bollinger Bands

Upper Band$40.47

Lower Band$39.36

%B Position280%(Upper)

Band Width1.02

RSI (14-Day)

Overbought

78.2

Momentum Oscillators

Stoch %K93.9

Stoch %D94.8

Williams %R-6.1

ROC (10d)2.0%

Momentum0.81

CCI (20d)207.0

MFI (14d)80.6

Volatility Measures

ATR (14d)$0.20(0.5%)

StdDev (20d)0.28

Hist Vol4.2%(Low)

Volume Flow

VWAP$40.50

OBV94.0M

AD Line16.8M

CMF (20d)0.478

Volume Metrics

Avg Vol (20d)2.2M

Vol RatioN/A

VWMA (20d)$40.03

Pivot Points

R3$40.50

R2$40.50

R1$40.50

Pivot Point$40.50

S1$40.50

S2$40.50

S3$40.50

Advanced Oscillators

TSI42.41

Ultimate Osc79.3

KST8.74

Financial Data

Quarter	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Total Revenue	$0	$0	$0	$0	$15.00M	$0	$0	$0	$0	$6.85M	$0	$0
Cost of Revenue	$238,599	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Gross Profit	$-238,599	$0	$0	$0	$15.00M	$0	$0	$0	$0	$6.85M	$0	$0

Operating Expenses	$79.77M	$68.47M	$53.79M	$54.65M	$45.78M	$74.58M	$46.41M	$43.98M	$36.09M	$42.03M	$40.21M	$47.02M
R&D	$59.89M	$54.48M	$41.56M	$42.74M	$33.44M	$60.87M	$33.90M	$32.81M	$22.65M	$29.72M	$28.19M	$33.67M
SG&A	$19.88M	$13.99M	$12.23M	$11.91M	$12.33M	$13.71M	$12.50M	$11.16M	$13.44M	$12.31M	$12.02M	$13.35M
Operating Income	$-79,773,000	$-68,472,000	$-53,790,000	$-54,653,000	$-30,777,000	$-74,580,000	$-46,405,000	$-43,980,000	$-36,090,000	$-35,178,000	$-40,209,000	$-47,019,000

Interest Income	$5.14M	$4.49M	$3.77M	$4.38M	$7.89M	$4.84M	$3.34M	$3.24M	$2.59M	$2.93M	$2.95M	$2.06M
Interest Expense	$2.73M	$2.81M	$2.89M	$2.88M	$2.88M	$2.48M	$2.56M	$2.52M	$2.53M	$2.57M	$2.54M	$2.45M
Income Before Tax	$-78,391,000	$-66,685,000	$-54,725,000	$-49,565,000	$-24,738,000	$-110,279,000	$-41,958,000	$-43,111,000	$-37,565,000	$-35,693,000	$-41,474,000	$-48,937,000
Income Tax Expense	$850,000	$-522,000	$166,000	$778,000	$1.40M	$1.05M	$608,000	$705,000	$481,000	$1.14M	$-2,826,000	$-24,051,000

Net Income	$-79,241,000	$-66,163,000	$-54,891,000	$-50,343,000	$-26,135,000	$-111,329,000	$-42,566,000	$-43,816,000	$-38,046,000	$-36,837,000	$-38,648,000	$-24,886,000

EBITDA	$-75,425,979	$-87,074,000	$-51,598,000	$-46,455,000	$-21,644,000	$-107,570,000	$-39,165,000	$-40,350,000	$-34,796,000	$-32,877,000	$-38,695,000	$-46,250,000
EBIT	$-75,664,578	$-87,315,000	$-51,835,000	$-46,681,000	$-21,861,000	$-107,800,000	$-39,401,000	$-40,586,000	$-35,036,000	$-33,123,000	$-38,933,000	$-46,487,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CNTA

News

Centessa Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Centessa Pharmaceuticals plc (NASDAQ: CNTA) and reminds investors of the November 28, 2022...

TMX Newsfile•Aug 4, 2026 8:48 PM ET8/4/26•Bearish

Centessa Pharmaceuticals (NASDAQ: CNTA) Medicxi group now reports 0% ownership

An amended Schedule 13G filing reveals that the Medicxi group, comprising several affiliated investment entities, now reports zero beneficial ownership of Centessa Pharmaceuticals plc Ordinary Shares. As of June 30...

Stock Titan•Aug 4, 2026 12:11 PM ET8/4/26•Somewhat-Bearish

Centessa Deadline Alert

Faruqi & Faruqi, LLP is investigating potential securities claims against Centessa Pharmaceuticals plc (NASDAQ: CNTA) and reminds investors of the November 28...

TMX Newsfile•Aug 4, 2026 11:17 AM ET8/4/26•Bearish

Centessa Pharmaceuticals PLC ADR Revenue Breakdown – MUN:260

Centessa Pharmaceuticals PLC ADR (MUN:260) generated 12.77 million EUR in revenue last year, primarily from its Clinical-stage Pharmaceutical segment. This segment contributed the entire revenue amount...

TradingView•Aug 1, 2026 5:40 AM ET8/1/26•Somewhat-Bullish

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Eli Lilly and Company announced a definitive agreement to acquire Centessa Pharmaceuticals for an upfront cash consideration of approximately $6.3 billion...

Eli Lilly and Company•Jul 22, 2026 9:10 AM ET7/22/26•Bullish

CNTA Competitors

Company	Ticker
GRAIL, LLC	GRAL
Kiniksa Pharmaceuticals Ltd	KNSA
Iovance Biotherapeutics Inc	IOVA
Rhythm Pharmaceuticals Inc	RYTM
Lantheus Holdings Inc	LNTH
Ligand Pharmaceuticals Incorporated	LGND
Amneal Pharmaceuticals, Inc. Class A Common Stock	AMRX
Immunovant Inc	IMVT

Sector: Healthcare

CNTA Bull Case vs Bear Case

Bear case

CNTA beat EPS estimates in 37.5% of its last 8 reported quarters.

CNTA Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -1.9%
EPS estimate (fiscal period ending Jun 30, 2026): $-0.38
Estimate revisions (30 days, fiscal period ending Jun 30, 2026): 2 up, 1 down

CNTA Dividend

Forward yield: 0.0%
Pay months: Jun

Frequently Asked Questions About CNTA

Does CNTA pay dividends?

Centessa Pharmaceuticals PLC ADR (CNTA) has a dividend payment track record. See the CNTA dividend history page for its current payment status, TTM yield, and recorded payments.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In

Earnings

Performance (10Y)

Upcoming Estimates

Dividends

Dividend Metrics

Key Metrics

Technical Indicators Dashboard

Moving Averages

MACD

ADX

Aroon & PSAR

Bollinger Bands

RSI (14-Day)

Momentum Oscillators

Volatility Measures

Volume Flow

Volume Metrics

Pivot Points

Advanced Oscillators

Financial Data

Related GNG Research

News

Centessa Deadline Alert

Centessa Pharmaceuticals (NASDAQ: CNTA) Medicxi group now reports 0% ownership

Centessa Deadline Alert

Centessa Pharmaceuticals PLC ADR Revenue Breakdown – MUN:260

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

CNTA Competitors

CNTA Bull Case vs Bear Case

Bear case

CNTA Earnings: Beat Rate and Next Report

CNTA Dividend

Frequently Asked Questions About CNTA

Related stocks

Get full access to GNG Research